{"id":11014,"date":"2023-10-15T15:27:00","date_gmt":"2023-10-15T13:27:00","guid":{"rendered":"https:\/\/www.adacyte.com\/?post_type=scientific-corner&p=11014"},"modified":"2025-08-07T15:51:08","modified_gmt":"2025-08-07T13:51:08","slug":"pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease","status":"publish","type":"scientific-corner","link":"https:\/\/www.adacyte.com\/fr\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/","title":{"rendered":"PP0882 EFFICACY AND SAFETY OF GRANULOCYTOAPHERESIS IN THE TREATMENT OF STEROID-DEPENDENT AND STEROID-REFRACTORY INFLAMMATORY BOWEL DISEASE"},"content":{"rendered":"
\n

N.D. Salazar Parada1, M. Algara San Nicolas1,A. Su\u00e1rez-Saro Fern\u00e1ndez1, A. Masedo1, C. Yela San Bernardino1,C. Bego\u00f1a1, P. Mart\u00ednez Montiel1, I. Fern\u00e1ndez V\u00e1zquez1<\/p>\n<\/div>\n\n

\n

UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations 15 October 2023 page 1047<\/p>\n<\/div>\n\n

\n

Introduction:<\/strong> Despite the importance of granulocytoapheresis (GCA) in the treatment of inflammatory bowel disease (IBD), its effectiveness in steroid-dependent and steroid-refractory IBD has not been widely evalu\u0002ated, the approaches are heterogeneous and data on efficacy and safety remain limited in our population.
Aims & Methods<\/strong>: This study aims to assess the effectiveness of GCA for in\u0002duction of remission and maintenance in patients with steroid-dependent and steroid-refractory IBD in the real-world practice.
Retrospective cohort of patients with steroid-dependent and steroid-\u0002refractory colonic IBD, in which GCA was used as induction of remission and maintenance treatment between January-2015 to January-2023. We
analyze demographics, disease characteristics, prior exposure including biologic agents. The success of GCA was defined on a decrease of at least 3 points in the True-love score for Ulcerative Colitis (UC) and a decrease of
at least 100 points in the CDAI for Crohn Disease (CD). To analyze predictive factors of treatment success we performed a univari\u0002ate and multivariable analysis.
Results<\/strong>: 49 patients were included. 5 cycles of apheresis were performed in the first 3 weeks as induction and at least 10 cycles of apheresis as main\u0002tenance in the next 6 months. <\/p>\n<\/div>\n\n

\n

75 % (37 \/ 49) had UC, 86.4 % (32 \/ 37) were steroid-refractory while 13.6 % (5 \/ 37) steroid-dependent, 54 % (20 \/ 37) male; median age 60 \u00b1 10.5 years with a mean of 10.5 years from diagnosis. 67.7 % (25 \/ 37) had received at least 1 biological treatment in the past, 43.5 % (17 \/ 39) \u2265 2 biological. After induction, 75 % (28 \/ 37) responded to treatment, 62 % (23 \/ 37) continued with maintenance therapy of which 67 % (15 \/ 23) responding. Mean PCR and calprotectin were 3,16 mg \/ dl and 2038 mg \/ dl before treatment, 1.45mg \/ dl and 1025 mg \/ dl after induction, 1.15 mg \/ dl and 900 mg \/ dl after maintenance, respectively. <\/p>\n<\/div>\n\n

\n

25 % (12 \/ 49) had CD, 50 % (6\/12) male; median age 62 \u00b1 9.8 years, 75% (9 \/ 12) steroid-refractory and 25 % (3 \/ 12) steroid-dependent, with a mean of 9 years from diagnosis, 67.7 % had received at least one biological
treatment in the past. After induction, 58 % (7 \/ 12) responded, 80 % (10 \/12) continued with maintenance with 50 % (5 \/ 10) responding. Mean CRP and calprotectin were 3.16 mg \/ dl and 3645 mg \/ dl before treatment, 1.7
mg \/ dl and 2473 mg \/ dl after induction, 1.14 mg \/ dl and 623 mg \/ dl after maintenance.
Factors such as smoking, extent of disease, longer disease course and lack of response to previous treatments, were not significantly related to re\u0002sponse in either induction or maintenance.
No patient had major adverse events recorded.
Conclusion: <\/strong>GCA appears to be safe and effective for inducing and main\u0002taining clinical remission in patients with IBD, especially in patients with UC. No significant differences were found in disease extension, duration or
lack of response to previous treatments.<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

N.D. Salazar Parada1, M. Algara San Nicolas1,A. Su\u00e1rez-Saro Fern\u00e1ndez1, A. Masedo1, C. Yela San Bernardino1,C. Bego\u00f1a1, P. Mart\u00ednez Montiel1, I. Fern\u00e1ndez V\u00e1zquez1 UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations 15 October 2023 page 1047 Introduction: Despite the importance of granulocytoapheresis (GCA) in the treatment of inflammatory bowel disease (IBD), its effectiveness in […]<\/p>\n","protected":false},"template":"","scientific_tags":[851,328,554,157,424,426,852,305,850,156,603,605],"class_list":["post-11014","scientific-corner","type-scientific-corner","status-publish","hentry","scientific_tags-biologic-exposed","scientific_tags-calprotectin","scientific_tags-colonic-mucosa","scientific_tags-efficacy","scientific_tags-gma","scientific_tags-ibd","scientific_tags-pcr","scientific_tags-retrsopective","scientific_tags-rwe","scientific_tags-safety","scientific_tags-steroid-dependent-2","scientific_tags-steroid-refractory-2"],"acf":{"sc_authors":"UEG Week 2023 Poster Presentations - 2023 - United European Gastroenterology Journal - Wiley Online Library<\/a>"},"yoast_head":"\nPP0882 EFFICACY AND SAFETY OF GRANULOCYTOAPHERESIS IN THE TREATMENT OF STEROID-DEPENDENT AND STEROID-REFRACTORY INFLAMMATORY BOWEL DISEASE - Adacyte<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PP0882 EFFICACY AND SAFETY OF GRANULOCYTOAPHERESIS IN THE TREATMENT OF STEROID-DEPENDENT AND STEROID-REFRACTORY INFLAMMATORY BOWEL DISEASE - Adacyte\" \/>\n<meta property=\"og:description\" content=\"N.D. Salazar Parada1, M. Algara San Nicolas1,A. Su\u00e1rez-Saro Fern\u00e1ndez1, A. Masedo1, C. Yela San Bernardino1,C. Bego\u00f1a1, P. Mart\u00ednez Montiel1, I. Fern\u00e1ndez V\u00e1zquez1 UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations 15 October 2023 page 1047 Introduction: Despite the importance of granulocytoapheresis (GCA) in the treatment of inflammatory bowel disease (IBD), its effectiveness in […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Adacyte\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-07T13:51:08+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/\",\"url\":\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/\",\"name\":\"PP0882 EFFICACY AND SAFETY OF GRANULOCYTOAPHERESIS IN THE TREATMENT OF STEROID-DEPENDENT AND STEROID-REFRACTORY INFLAMMATORY BOWEL DISEASE - Adacyte\",\"isPartOf\":{\"@id\":\"https:\/\/www.adacyte.com\/#website\"},\"datePublished\":\"2023-10-15T13:27:00+00:00\",\"dateModified\":\"2025-08-07T13:51:08+00:00\",\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/\"]}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.adacyte.com\/#website\",\"url\":\"https:\/\/www.adacyte.com\/\",\"name\":\"Adacyte\",\"description\":\"Adacyte Therapeutics\",\"publisher\":{\"@id\":\"https:\/\/www.adacyte.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.adacyte.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.adacyte.com\/#organization\",\"name\":\"Adacyte\",\"url\":\"https:\/\/www.adacyte.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"contentUrl\":\"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg\",\"width\":165,\"height\":46,\"caption\":\"Adacyte\"},\"image\":{\"@id\":\"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PP0882 EFFICACY AND SAFETY OF GRANULOCYTOAPHERESIS IN THE TREATMENT OF STEROID-DEPENDENT AND STEROID-REFRACTORY INFLAMMATORY BOWEL DISEASE - Adacyte","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/","og_locale":"fr_FR","og_type":"article","og_title":"PP0882 EFFICACY AND SAFETY OF GRANULOCYTOAPHERESIS IN THE TREATMENT OF STEROID-DEPENDENT AND STEROID-REFRACTORY INFLAMMATORY BOWEL DISEASE - Adacyte","og_description":"N.D. Salazar Parada1, M. Algara San Nicolas1,A. Su\u00e1rez-Saro Fern\u00e1ndez1, A. Masedo1, C. Yela San Bernardino1,C. Bego\u00f1a1, P. Mart\u00ednez Montiel1, I. Fern\u00e1ndez V\u00e1zquez1 UEG journal 2023 SUPPLEMENT ABSTRACT UEG Week 2023 Poster Presentations 15 October 2023 page 1047 Introduction: Despite the importance of granulocytoapheresis (GCA) in the treatment of inflammatory bowel disease (IBD), its effectiveness in […]","og_url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/","og_site_name":"Adacyte","article_modified_time":"2025-08-07T13:51:08+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/","url":"https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/","name":"PP0882 EFFICACY AND SAFETY OF GRANULOCYTOAPHERESIS IN THE TREATMENT OF STEROID-DEPENDENT AND STEROID-REFRACTORY INFLAMMATORY BOWEL DISEASE - Adacyte","isPartOf":{"@id":"https:\/\/www.adacyte.com\/#website"},"datePublished":"2023-10-15T13:27:00+00:00","dateModified":"2025-08-07T13:51:08+00:00","inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.adacyte.com\/professional\/scientific-corner\/pp0882-efficacy-and-safety-of-granulocytoapheresis-in-the-treatment-of-steroid-dependent-and-steroid-refractory-inflammatory-bowel-disease\/"]}]},{"@type":"WebSite","@id":"https:\/\/www.adacyte.com\/#website","url":"https:\/\/www.adacyte.com\/","name":"Adacyte","description":"Adacyte Therapeutics","publisher":{"@id":"https:\/\/www.adacyte.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.adacyte.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.adacyte.com\/#organization","name":"Adacyte","url":"https:\/\/www.adacyte.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","contentUrl":"https:\/\/www.adacyte.com\/wp-content\/uploads\/2021\/01\/logo-adacyte.svg","width":165,"height":46,"caption":"Adacyte"},"image":{"@id":"https:\/\/www.adacyte.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner\/11014","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific-corner"}],"about":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/types\/scientific-corner"}],"wp:attachment":[{"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/media?parent=11014"}],"wp:term":[{"taxonomy":"scientific_tags","embeddable":true,"href":"https:\/\/www.adacyte.com\/fr\/wp-json\/wp\/v2\/scientific_tags?post=11014"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}